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1. Introduction 
Neither hepatitis B virus (HBV) nor hepatitis C virus (HCV) is cytopathic, and hepatitis is 
caused by the host immune response against virus-related peptides expressed on 
hepatocytes in conjunction with human leukocyte antigens (HLA). In acute self-limiting 
hepatitis, a broad immune response occurs that is strong enough to eradicate the virus or 
suppress viral replication (Rehermann, 1996). However, there are many mechanisms that 
hamper the antiviral immune response leading to persistent infection. To develop an 
optimal strategy to stimulate antiviral immune response with therapeutic potential, 
extensive analyses of immune mechanisms for successful viral eradication and 
immunosuppressive mechanisms induced by viral infection during persistent infection are 
required. The first half of this chapter discusses these points, followed by a discussion of 
immunotherapeutic approaches in both animal models and humans in the second half. 
2. Immunological response in viral infection 
2.1 Acute viral hepatitis 
Immunological analysis has been extensively performed in transgenic and chimpanzee 
models of acute HBV infection. In one model, transgenic mice, in which infectious HBV 
virions replicate in the liver with expression of all HBV-related antigens, were injected with 
HBsAg-specific cytotoxic T lymphocytes (CTLs) that had been induced in nontransgenic 
mice. The injected CTLs produced interferon (IFN)- and tumor necrosis factor (TNF)-, 
which purged viral RNA and DNA without destroying infected hepatocytes (Guidotti et al., 
a 1996; Chisari, 1997; Guidotti et al., 2001). Importantly, this noncytolytic clearance of 
intracellular HBV is more efficient at controlling HBV replication than the killing of infected 
hepatocytes. In this sense, hepatitis is not only a harmful event but also represents an 
effective mechanism by which CTLs suppress HBV. It is important to note that in the HBV 
transgenic mouse model of acute hepatitis, administration of antibodies against the 
chemokines, IFN--inducible protein (IP-10) and monokine induced by interferon- (Mig) 
reduced the recruitment of mostly Ag-nonspecific mononuclear cells into the liver that had 
been induced by cytokines and chemokines produced by injected CTLs, leading to a 
reduction in the severity of hepatitis without affecting the antiviral activity of the CTLs 
(Kakimi et al., 2001). These observations have important therapeutic implications, because 
suppression of Ag-nonspecific mononuclear cell recruitment may suppress hepatitis while 
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retaining the antiviral function of the CTLs. Noncytolytic viral eradication can account for 
recovery from acute HBV infection in that most HBV is cleared from hepatocytes with only a 
fraction of the hepatocytes being destroyed. This was confirmed in a chimpanzee infection 
model; HBV DNA level was markedly decreased in the liver and blood of acutely infected 
chimpanzees before peak serum alanine aminotransferase (ALT) concentrations were 
reached (Guidotti et al., 1999), suggesting that this noncytopathic T cell effector mechanism 
results in early viral inhibition or eradication, whereas a cytopathic T cell effector 
mechanism would be required to eliminate the remaining virus by destroying infected 
hepatocytes.  
In humans, the HBV-specific T cell response during incubation phase of acute hepatitis B 
has been analyzed extensively using HLA class I tetramer and cytokine staining (Webster et 
al., 2000). The data showed that maximal reduction in HBV DNA in the serum occurred 
before the peak of ALT elevation, again indicating that suppression of HBV replication 
occurs without hepatocyte injury. Moreover, infiltration of HBV-specific CD8+ T cells into 
the liver has been observed several weeks before the peak of liver injury, suggesting that 
HBV-specific T cell infiltration occurs at an early stage of infection resulting in suppression 
of HBV replication. Thereafter, recruitment of mostly nonspecific cells induced by cytokines 
or chemokines produced by HBV-specific T cells contributes to significant liver damage.  
The overall data from studies in mice, chimpanzees, and humans are essentially the same, 
and indicate that a sufficient T cell response to HBV at an early phase of infection is 
important for eradication of virus infection, and that an insufficient T cell response may lead 
to persistent viral infection.  
The same is essentially true in acute HCV infection. Multispecific and vigorous CTL 
responses against HCV antigens are important for successful eradication of the virus. 
Moreover, a CD4+ T cell response at an early stage of acute infection and persistence of the 
response are apparent in acute infection (Semmo et al., 2007). In contrast to acute HBV 
infection, the majority of patients with acute HCV infection progress to persistent infection, 
and the mechanisms underlying failure to eradicate the virus have been analyzed. The 
failure of CD4+ T cell function is a key factor in HCV persistence and CD4+ T cells from 
persistent infection do not produce Th1 cytokines, such as IFN- and IL-2, but produce IL-4 
and IL-10, clearly distinct from those seen in patients with recovery (Tsai et al., 1997). 
Moreover, an early and strong Th1 response has been shown to play an important role in 
disease resolution. One possible mechanism explaining why the Th2 type CD4+ T cell 
response is dominant in patients with persistent infection is a defective function of dendritic 
cells, possibly due to lack of IL-12 production (Fowler et al., 2003).  
2.2 Antigen-specificity of T cell response in viral hepatitis 
The antigen-specificity of the T cell response to HBV in acute hepatitis has been analyzed, 
and it is clear that acute viral hepatitis involves a vigorous CTL response to multiple 
epitopes in the viral nucleocapsid, envelope, and polymerase proteins, while these are not 
seen in patients with chronic hepatitis (Rehermann, 1996). Although multi-specificity of the 
CTL response is characteristic in acute hepatitis, there is known to be a hierarchy of epitope-
specific CD8+ T cell responses determined by cytokine production after peptide stimulation. 
In acute hepatitis B, CD8+ T cell response to HBc18-27 (HLA-A2 restricted epitope) is 
dominant followed by the response to polymerase epitope (455 – 463), whereas envelope 
epitopes are always subdominant (Webster et al., 2001). The hierarchy is clearly distinct 
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from that observed in chronic hepatitis, in which the CD8+ T cell response to envelope 
epitope (183 – 191) is always dominant. Interestingly, chronic hepatitis patients with lower 
HBV DNA levels in the serum show greater responses to HBc18-27 than those with high 
HBV DNA. These findings imply that the T cell response to HBcAg is important for viral 
control, which is important for designing peptide vaccines for the treatment of chronic HBV 
infection. 
In acute HCV infection, the CTL responses were directed against multiple viral epitopes, in 
particular within the structural (core) and nonstructural (NS) regions of the virus (NS3, NS4, 
and NS5), and the CTL frequencies were higher in patients with acute infection (Cucchiarini 
et al., 2000; Lechner et al., 2000) than in those who develop persistent infection. The 
hierarchy of HCV epitopes has not been analyzed extensively, but resolution of primary 
infection in the chimpanzee was shown to be associated with a dominant CD4+ T cell 
response against epitopes including NS3 (GYKVLVLNPSV), suggesting the existence of an 
HCV epitope hierarchy (Shoukry et al., 2004). 
2.3 Chronic hepatitis 
In contrast to acute hepatitis, the T cell response to HBV is weak and is narrowly focused in 
chronically infected patients (Chisari et al., 1995), suggesting that it may be a cause of 
persistent infection.  
HBV-specific helper and cytotoxic T lymphocytes (CTLs) are barely detectable in peripheral 
blood of patients with chronic hepatitis B (Ferrari et al., 1990), possibly due to exhaustion by 
high viral load or tolerance to HBV. Maini et al. (2000) reported that the number of HBV-
specific T cells, detected using tetramers was the same in livers with low HBV DNA/ALT as 
in those with high HBV DNA/ALT. Hence, HBV-specific T cells recognize HBV antigens 
and carry out immune surveillance in the liver. Thus, they have an important role in 
controlling HBV replication in the liver without causing hepatic necroinflammation in low 
DNA/ALT anti-HBe+ HBV carriers. It remains unknown why HBV-specific T cells fail to 
effectively control HBV replication in the liver with chronic hepatitis. However, recent 
advances in immunology have given some insight into the mechanism as described below. 
In contrast to chronic HBV infection, CTL response against various HCV epitopes including 
core, envelope and NS regions can be detected in chronic HCV infection, especially in liver-
infiltrating lymphocytes (Koziel et al, 1995). Although intrahepatic CTL response was 
shown associated with low viral load (Freeman et al, 2003), the CTL response is not enough 
to terminate HCV infection possibly due to the presence of immunosuppressive 
mechanisms similar to chronic HBV infection.  
3. Immunosuppressive mechanisms responsible for persistent hepatitis virus 
infection 
3.1 Regulatory T cells (Tregs) 
Tregs expressing the forkhead family transcription factor, Foxp3, are specialized cells that 
exert negative control on a variety of physiological and pathological immune responses, 
resulting in maintenance of immunological self-tolerance (Miyara et al., 2011). They show 
diverse phenotypes, occurring in both CD4+ and CD8+ T cell subsets, and express CD25 
(IL-2 receptor  chain) and/or cytotoxic T-lymphocyte antigen 4 (CTLA-4) in addition to 
Foxp3. 
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In HBV infection, HBeAg-positive patients with high HBV DNA levels in the serum showed 
elevated numbers of CD4+CD25+ Treg cells in the blood compared to patients with acute or 
chronic HCV infection (Xu et al., 2006). Significant accumulation of CD4+CD25+FoxP3+ Treg 
cells in the liver was found in patients with chronic HBV infection. Moreover, patients with 
high viral load have a higher proportion of Tregs in the liver (Stoop et al., 2008), suggesting 
that intrahepatic Tregs suppress antiviral immune responses in the liver in chronic hepatitis 
B virus infection. In HCV infection, it has also been shown that a higher frequency of 
CD4+CD25+ regulatory T cells in the blood of chronically HCV-infected patients versus 
recovered or healthy individuals (Cabrera et al., 2004; Boettler et al., 2005) and the presence 
of CD4+FoxP3+ T cells in the liver of chronically HCV-infected patients (Sturm et al., 2010).  
3.2 Programmed Death-1 (PD-1) 
PD-1 is a surface receptor critical for the regulation of T cell function (Francisco et al., 
2010; Fife et al., 2011). Binding to PD-1 by its ligands PD-L1 and PD-L2 results in the 
antigen-specific inhibition of T cell proliferation, cytokine production, and cytolytic 
function, leading to exhaustion of T cells. In the liver, PD-1 is expressed on lymphocytes; 
PD-L1 is expressed on lymphocytes, hepatocytes, and sinusoidal endothelial cells, and 
PD-L2 is expressed on Kupffer cells and DCs (Chen et al., 2010). HBeAg-positive patients 
with high HBV DNA levels in the serum showed increased PD-1 and CTLA-4 expression 
on HBV-specific CD8+ T cells (Peng et al., 2011). Moreover, PD-1 expression on CD4+ T 
cells is correlated positively with serum HBV DNA load in CHB patients (Nan et al., 
2010). Intrahepatic HBV-specific CD8+ T cells express higher levels of PD-1, and 
upregulation of intrahepatic PD-1/PD-L1 is associated with liver inflammation and ALT 
elevation (Fisicaro et al., 2010). Although the mechanism underlying the upregulation of 
PD-1 on CD8+ T cells in the inflamed liver is unknown, signals from PD-1 inhibit HBV-
specific T cells, resulting in insufficient antiviral responses leading to failure of viral 
control and persistent liver inflammation. Importantly, PD-1/PD-L1 blockade increased 
CD8+ T cell proliferation and enhanced IFN- and IL-2 production by intrahepatic 
lymphocytes (Fisicaro et al., 2010). These findings suggest that inhibition of PD-1/PD-L1 
may have therapeutic potential for the control of hepatitis B. 
Similar to T cells in patients with chronic hepatitis B, circulating and intrahepatic HCV-
specific CD8+ T cells were found to express high levels of PD-1 (Golden-Mason et al., 2007), 
and PD-1 expression level in the liver is higher than that in peripheral blood. Increased 
expression of PD-1 is associated with CD8+ T cell dysfunction, and functional restoration is 
achieved by blocking the signal from PD-1 (Penna et al., 2007). Recently, HCV core protein 
was shown to induce PD-1 and PD-L1 on T cells from healthy donors (Yao et al., 2007), 
indicating that immunosuppressive ability of HCV core protein is mediated by the 
upregulation of inhibitory molecules on T cells. Increased PD-1 expression on HCV-specific 
CTLs was reported to be significantly associated with poor response to antiviral therapy 
(Golden-Mason et al., 2008), and PD-L1 expression on DCs is increased during IFN-a 
treatment (Urbani et al., 2008), suggesting that PD-1/PD-L1 is associated with the efficacy of 
antiviral treatment. PD-1 is also expressed on Tregs in the liver, and the signal from PD-1 
ligation provides an overall inhibitory signal to Tregs. PD-1 blockade enhanced IL-2-
dependent proliferation of intrahepatic Tregs in response to HCV antigens and enhanced 
the inhibitory ability of Tregs ((Franceschini et al. 2009), suggesting that complex 
interactions determine the direction of antiviral immune response. 
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3.3 Interluekin-10 (IL-10) 
Interleukin (IL)-10 is an important cytokine with anti-inflammatory properties, and is 
produced by activated monocytes/macrophages and T cell subsets, including Treg and Th1 
cells (Sabat et al., 2010). Immunosuppression by IL-10 is associated with functional 
exhaustion of memory T cells in chronic lymphocytic choriomeningitis virus (LCMV) 
infection, and blockade of IL-10 receptors could terminate chronic LCMV infection (Ejrnaes 
et al., 2006). In chronic HBV infection, HBcAg stimulates the production of IL-10, which 
negatively regulates HBcAg-specific Th17 cell responses in CHB patients (Li et al., 2010). 
In HCV infection, peripheral blood mononuclear cells produce IL-17, IFN-, IL-10, and TGF-
 in response to NS4 protein of HCV, and neutralization of TGF- or IL-10 significantly 
enhances NS4-specific IL-17 and IFN- production by T cells from HCV-infected patients 
(Rowan et al., 2008). Moreover, lipopolysaccharide and HCV core protein trigger IL-10 and 
TNF- production from monocytes, but at much lower levels from monocytes in patients 
with self-limiting HCV infection (Martin-Blondel et al., 2008). These data indicate that HCV 
proteins induce IL-10 from monocytes in patients with chronic HCV infection, leading to 
suppression of antiviral immune response. 
3.4 T-cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) 
It has been reported that not all exhausted T cells show upregulation of PD-1 and 
downregulation of CD127 (IL-7 receptor), and blockade of the PD-1/PD-L1 signaling 
pathway does not always restore proliferation and cytokine production (Golden-Mason et 
al., 2009). Recently, another inhibitory molecule, Tim-3, has been reported. A high frequency 
of Tim3-expressing CD4+ and CD8+ T cells are found in chronic HBV infection, and the 
frequency of Tim-3+ T cells was positively correlated with the severity of liver inflammation, 
and negatively correlated with plasma IFN- levels (Ju et al., 2009). Tim-3 was also highly 
expressed on CD4+ and CD8+ T cells in HCV infection, with the highest levels seen on HCV-
specific CTLs. Tim-3 expression is associated with reduced Th1/Tc1 cytokine production, 
and blocking the Tim-3 – Tim-3 ligand interaction could enhance CD4+ and CD8+ T cell 
proliferation in response to HCV-specific antigens (Golden-Mason et al., 2009). 
3.5 Dysfunction of DCs 
DCs are specialized antigen-presenting cells that orchestrate immune responses. They 
stimulate innate and acquired immune responses, but also act as tolerogenic cells for 
immune responses in a variety of situations. In viral hepatitis, dysfunction of DCs from 
peripheral blood has been reported. In patients with chronic hepatitis B, maturation of DCs 
from peripheral blood of patients after incubation with cytokines is lower than that of 
normal subjects with lower expression of HLA-DR and costimulatory molecules in the 
former population (Wang et al., 2001), leading to low allostimulatory function of DCs from 
CHB patients. The mechanism of impairment of DC function in patients with chronic 
hepatitis B is unclear, but both HBV particles and purified HBsAg may have 
immunomodulatory capacity and may directly contribute to the dysfunction of myeloid 
DCs (Op den Brouw et al., 2009). Importantly, impaired function of monocyte-derived DCs 
from patients with CHB could be reversed by inhibiting viral replication with nucleoside 
analogs such as lamivudine (Beckebaum et al., 2003). Type 2 precursor plasmacytoid 
dendritic cells (pDCs), which are the most important cells in antiviral innate immunity, were 
also reported to have quantitative and qualitative impairment in patients with chronic HBV 
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infection (Duan et al., 2004). Recently, HBV itself was shown to inhibit the functions of pDCs 
(Woltman et al., 2011). These data indicate that DCs in patients with chronic hepatitis B have 
impaired function leading to insufficient T cell response to HBV, which could be the 
mechanism responsible for persistent viral infection. 
In chronic hepatitis C, DCs from patients also show impaired immunostimulatory function, 
which could be induced by HCV (Eksioglu et al., 2010) or NS4 protein (Takaki et al., 2010). 
Monocyte-derived DCs from HCV patients were shown to induce proliferation of 
CD4+CD25+FoxP3+ regulatory T cells, which limit proliferation of HCV-specific T 
lymphocytes (Dolganiuc et al., 2008). DCs in HCV patients thus inhibit T cell responses via a 
variety of mechanisms.  
4. Immunotherapy for viral hepatitis 
Therapeutic strategies for terminating viral infection should be evaluated based on the 
mechanisms responsible for insufficient antiviral immunological mechanisms leading to 
persistent viral infection. Most immunotherapeutic approaches for viral hepatitis have been 
directed against hepatitis B. This is likely due to the availability of good animal models of 
persistent HBV infection, ready availability of HB vaccine and accumulation of basic 
immunological analyses. Previous animal studies and human trials are listed in Tables 1 and 
2, respectively.  
 
Peptide vaccination 
Wang et al. 2010; A synthesized fusion peptide, consisting of HBcAg18-27 and HIV Tat49-
57 adjuvanted with CpG ODN increased CD3+, CD4+ and CD8+ cells and the production 
of IFN- and IL-2. Vaccination with the peptide reduced serum HBV DNA levels and 
decreased the expression levels of HBsAg and HBcAg in the livers of transgenic mice. 
Protein vaccination 
Akbar et al, 1997; HBV transgenic mice were treated with vaccine on the base of surface 
antigen in complete Freund's adjuvant once a month for 12 months. Most of the mice 
showed reduction of HBV DNA level and disappearance of HBeAg and HBsAg. 
Menne et al, 2007; A combination of conventional vaccine on the base of the WHV large 
surface protein contained HBsAg with pre-S and clevudine significantly restored the T-
cell response to Pre-S and S region in chronic WHV infection.  
Miller at al, 2008; One hour post-infection with DHBV, DNA vaccine expressing DHBc 
and Pre-S/S and entecavir were given simultaneously and continued for 14 days. Ducks 
boosted with fowl poxvirus vectors expressing DHBc and Pre-S/S showed clearance of 
DHBV infection at a rate of 100%. 
DNA immunization 
Thermet et al, 2008; DNA vaccine encoding the DHBV large envelope and/or core 
protein was given 6 times with or without lamivudine in a DHBV model. Reduction of 
viremia and liver DHBV cccDNA was observed in 33% of ducks receiving DNA vaccine 
mono- or combination therapy. Seroconversion to anti-pre S was observed in 67% of 
ducks showing cccDNA clearance. 
Encke et al, 2006; The combination of DNA vaccination encoding HCV core and mouse 
IL-2 breaks tolerance and activates previously tolerant T cells in an HCV transgenic 
mouse model. 
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DC immunization 
Shimizu et al, 1998; Activated bone marrow-derived DCs were shown to break CTL 
tolerance to HBsAg in HBV transgenic mice. 
Kimura et al, 2002; A single injection of an anti-CD40 agonistic monoclonal antibody into 
HBV transgenic mice induced noncytopathic inhibition of HBV replication, which was 
mediated by antiviral cytokines (IL-12 and TNF-) produced by activated intrahepatic 
antigen-presenting cells. 
Jiang et al, 2008; HBV transgenic mice were injected with HBV-specific peptide-pulsed 
DCs, and significant reductions in the serum HBsAg and HBV DNA concentrations were 
observed. 
Díaz-Valdés et al, 2011; DCs, treated with peptide inhibitors of IL-10, induced strong anti-
HCV T cell responses in HCV transgenic mice. 
Cytokines and adjuvants 
Cavanaugh et al, 1997; Recombinant IL-12 markedly inhibits HBV replication in the liver 
of HBV transgenic mice through its ability to induce IFN-.  
Kakimi et al, 2000; A single injection of -galactosylceramide that can activate 
Valpha14+NK1.1+T cells (NKT cells) abolished HBV replication in HBV transgenic mice. 
Kimura et al, 2002; Injection of IL-18 into HBV transgenic mice inhibited HBV replication 
noncytopathically, which was mediated by activation of resident intrahepatic NK cells 
and NKT cells.  
Gene therapy 
Hong et al, 2011; Lentivectors expressing HBsAg and IgFc fusion Ag could effectively 
break immune tolerance and induced seroconversion to anti-HBs in HBsAg transgenic 
mice. 
CpG ODN; CpG oligodeoxynucleotide, WHV; woodchuck hepatitis virus, DHBV; duck hepatitis B 
virus, cccDNA; covalently closed circular DNA, NKT; natural killer T 
Table 1. Immunotherapeutic approaches for animal models of HBV and HCV infection.  
 
Peptide vaccination 
Heathcote et al, 1999; A vaccine with HBc18-27 peptide comprised of a T-helper cell 
epitope and two palmitic acid residues was administered to chronic hepatitis B (CHB) 
patients. Low levels of CTL activity were induced, but no significant changes in liver 
biochemistry or viral serology were observed. 
Klade et al, 2008; A vaccine containing 7 relevant HCV T cell epitopes and the Th1 
adjuvant poly-L-arginine, induced HCV-specific Th1/Tc1 responses in a subset of HCV 
patients not responding to or relapsing from standard therapy. However, only a minimal 
decrease in HCV viremia was induced by the vaccination. 
Yutani et al, 2009; Vaccination with a peptide derived from HCV core protein induced 
both cellular and humoral responses in nearly all HCV patients with different HLA class 
I-A alleles, and reduced serum ALT and -fetoprotein levels in 29% and 50% of patients, 
respectively. 
Protein vaccination 
Pol et al; 2001; Five intramuscular injections of 20g of a preS2/S (GenHevac B) or S 
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(Recombivax) vaccine in CHB patients showed HBe/anti-HBe seroconversion in 13% and 
HBV DNA negativity in 16% of the treated patients. 
Dahmen et al, 2002; Intradermal commercially available HBV vaccine and laimvudine in 
combination with IL-2 induced a significant antiviral response, leading to HBV DNA loss 
in the serum in two of five patients with chronic hepatitis B. 
Klein et al, 2003; Oral administration of HBV envelope proteins (HBsAg+preS1+preS2) to 
CHB patients three times a week for 20 to 30 weeks induced histological improvement in 
30% of the patients, HBeAg negativity in 26.3% and HBsAg-specific T cell proliferation in 
78%. 
Helvaci et al, 2003; Children with CHB were treated with IFN--2b monotherapy (9 
months) or IFN--2b plus HBV pre-S2/S vaccine (0, 4, 24weeks). The patients who 
received the combination therapy showed a greater reduction in HBV DNA than those 
who received IFN--2b monotherapy. 
Vandepapelière et al, 2007; In HBeAg-positive CHB patients, the combination with 
lamivudune and vaccine on the base of surface antigen with adjuvant did not improve 
the HBe seroconversion rate in comparison with lamivudine therapy alone. 
Senturk et al, 2009; CHB patients who were treated with lamivudine and vaccine on the 
base of surface antigen showed sustained negativity of HBV DNA in 1/4 of the treated 
patients. 
Al-Mahtab et al, 2010; CHB patients were treated with lamivudine and vaccine on the 
base of surface antigen (5 times) for 12 months. HBV DNA became undetectable in 64% of 
the patients, and was decreased in the remaining patients at the end of the combination 
therapy. No patients showed ALT elevation. 
DNA immunization. 
Mancini-Bourgine et al, 2004; DNA vaccine encoding HBV envelope protein induced an 
increase in HBV-specific IFN--secreting T cells in patients with CHB, who had been 
nonresponders to conventional therapies, and HBV DNA levels were transiently 
decreased in 50% of vaccinated patients.  
Mancini-Bourgine et al, 2006; DNA vaccine encoding PreS and S was administered to 
HBeAg+ CHB patients with lamivudine breakthrough, and the patients developed IFN--
producing T cells specific for preS or S antigen. Two of 10 patients showed 
seroconversion to anti-HBe. 
Alvarez-Lajonchere et al; 2009; A new vaccine, CIGB0230, consisting of a mixture of 
plasmid expressing HCV structural antigens and HCV recombinant core protein, Co.120 
was intramuscularly administered 6 times within 20 weeks in patients with chronic HCV 
infection. The vaccination induced specific T cell proliferation and IFN- production in 
73%. More than 40% of vaccinees showed improvement of liver histology, despite 
persistent detection of HCV RNA. 
DC immunization 
Chen et al, 2005; Peripheral blood-derived DCs, activated with GM-CSF and IL-4, were 
pulsed with HBsAg, and were administered subcutaneously twice in CHB patients. Both 
patients with normal and elevated ALT responded equally to DC vaccine and 53% of the 
patients showed induction of HBeAg negativity.  
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Luo et al, 2010; Activated DCs were generated from CD14+ cells of PBL with GM-CSF and 
IL-4, and two peptides, HBcAg18-27 and PreS244-53, were loaded. Aliquots of 5x106 to 
3x107 DCs were infused intravenously, and reinfusion was performed once or twice a 
month for 3 months. Undetectable HBV DNA was achieved in 46.3% and 3.13% of 
HBeAg- and HBeAg+ patients, respectively. ALT normalization was observed in 69% of 
HBeAg- patients and in 30.5% of HBeAg+ patients. 
Gowans et al, 2010; Monocyte-derived DCs loaded with lipopeptides consisting of HCV-
specific HLA-A2.1-restricted CTL epitopes, can induce HCV-specific CD8+ T cell 
responses with IFN- production in PBL in HCV patients in whom conventional IFN-
based therapy has failed. However, ALT levels were not elevated and viral load was not 
decreased.  
Cytokines 
Martin et al, 1993; Granulocyte macrophage-colony stimulating factor (GM-CSF) was safe 
and tolerable up to 1.0g/kg body wt, and induced HBV DNA negativity in 4/8 patients 
with chronic HBV infection. 
Wang et al, 2002; Combination therapy with GM-CSF (50g) and vaccine on the base of 
surface antigen (10g) (four intramuscular injections) significantly reduced serum HBV 
DNA in HBV carrier children. 
Zeuzem et al, 2001; HBV DNA clearance was observed in 25% of CHB patients treated 
with a high dose of IL-12 (0.5g/kg), and a reduction of >50% in HCV RNA level was 
observed in 53% of CHC patients treated with the same dose of IL-12. 
Rigopoulou et al, 2005; The addition of IL-12 to lamivudine therapy stimulated T cell 
response to HBV with IFN- production. However, IL-12 was unable to suppress re-
elevation of HBV DNA after cessation of lamivudine. 
Szkaradkiewicz et al, 2005; Combination of IL-12 and IL-18 stimulated IFN- production 
by CD4+ T cells isolated from peripheral blood of children with chronic hepatitis B in 
response to HBcAg, and the effect was greater than those observed with either cytokine 
alone. 
Woltman et al, 2009; -galactosylceramide was administered to patients with chronic 
HBV infection. It was poorly tolerated and showed no clear suppressive effect on serum 
HBV DNA or ALT levels. 
Thymosin- 1 (Talpha1) 
Arase et al, 2003; The combination of Talpha1 and IFN- for 24 weeks showed no 
statistically significant differences as compared with IFN- monotherapy with respect 
to HBeAg seroconversion, changes in histology, normalization of ALT or loss of HBV 
DNA. 
Iino et al, 2005; CHB patients were treated with Talpha1 for 24 weeks. At 12 months after 
cessation of therapy, 36.4% of patients treated with 1.6mg of Talpha1 achieved ALT 
normalization, 15% achieved HBV DNA clearance by transcription-mediated 
amplification, and 22.8% achieved clearance of HBeAg.  
You et al, 2006; Efficacy of Talpha1 treatment was compared with IFN-, and Talpha1 
treatment was more effective in achieving ALT normalization and HBV DNA negativity 
at the end of the follow-up period than IFN-. 
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Lee et al, 2008; The combination of Talpha1 and lamivudine did not show any additional 
antiviral effect compared with lamivudine monotherapy as determined by HBe 
seroconversion and the emergence of viral breakthrough. 
Zhang et al, 2009; A meta analysis demonstrated that combination therapy with 
lamivudine and Talpha1 yielded significantly higher rates of ALT normalization, 
virological response, and HBeAg seroconversion than lamivudine monotherapy.  
Poo et al, 2008; Patients with chronic HCV infection who had been nonresponders to 
prior IFN- and ribavirin were treated with Talpha1, PEG-IFN -2a, and ribavirin for 48 
weeks. Twenty-four percent of the treated patients with genotype 1 achieved a sustained 
virological response. 
GM-CSF; granulocyte macrophage-colony stimulating factor 
Table 2. Immunotherapeutic trials for chronic HBV and HCV infection in humans  
5. Immunotherapeutic approaches for viral hepatitis (Table 1 and 2) 
Immunotherapeutic strategies for viral hepatitis include suppression of viral replication, 
induction of immune response to hepatitis virus, activation of nonspecific cells, and 
administration of cytokines with antiviral activity. 
5.1 Suppression of viral replication 
High viral load has been shown to suppress CD4+ and CD8+ T cells in addition to induction 
of Tregs, which could be reversed by antiviral therapy (Boni et al., 2001). Therefore, 
immunotherapy followed by restoration of virus-specific T cell response with antiviral 
therapy could be more efficient, especially in CHB.  
5.2 Induction of immune response to hepatitis virus 
5.2.1 Peptide immunization 
A peptide vaccine containing highly immunogenic HBc18-27 has been developed and 
administered to CHB patients (Heathcote et al., 1999), but the results were disappointing 
because there was no induction of a significant antiviral T cell response. There have also 
been no reports of efficient peptide vaccination in HCV infection. 
5.2.2 Protein immunization 
In a model of HBV in transgenic mice, vaccine on the base of surface antigen in complete 
Freund’s adjuvant once a month for 12 months induced reduction in HBV DNA, and the 
disappearance of HBeAg and HBsAg in most mice treated. Moreover, it is important to note 
that some mice developed anti-HBs in the sera (Akbar et al., 1997). However, several human 
trials with vaccine on the base of surface antigen showed limited efficacy if used as 
monotherapy.  
Recently, HB vaccine containing not only S protein but also preS has been used with 
increased immunogenicity (Pol et al., 2001, Klein et al., 2003), or has been combined with 
lamivudine or IFN- (Helvaci et al., 2003) leading to potential improvement of clinical 
efficacy. However, analysis on the T cell epitope hierarchy indicated that the most important 
epitope for viral control is HBc18-27, and not the HBsAg epitope in HLA-A2 patients 
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(Webster et al., 2001), suggesting the necessity of reconsidering antigen selection for 
vaccination that could lead to better viral control.  
5.2.3 DNA immunization 
Injection of plasmid DNA has been shown to strongly elicit both cellular and humoral 
immune responses, and is now known to be safe and well-tolerated both in mice and 
humans. In a model of duck hepatitis B virus infection, DNA vaccine encoding HBV large 
envelope and/or core protein was shown to induce reduction in not only viremia but also 
cccDNA in the liver in one third of ducks receiving DNA monotherapy or combination 
treatment along with lamivudine (Thermet et al., 2008). This finding is encouraging because 
clearance of cccDNA from the liver is the goal of treatment for HBV infection, but is difficult 
to achieve using IFN- or nucleoside analogs. Clinical trials have also been performed in 
both HBV and HCV infection with some encouraging results (Table 2), which remain to be 
confirmed by future randomized large-scale trials.  
5.2.4 DC immunization 
DCs are specialized antigen-presenting cells that can induce strong immune responses in T 
and B cell. We have previously shown that activated bone marrow-derived DCs can break 
CTL tolerance to HBsAg in HBV transgenic mice (Shimizu et al., 1998). Thereafter, several 
immunotherapies with activated DCs have been applied in both animals and humans (Table 
1 and 2). In a recent study performed in HBV transgenic mice, peptide-pulsed DCs were 
shown to significantly reduce the concentrations of serum HBsAg and HBV DNA (Jiang et 
al., 2003), indicating therapeutic potential in chronic HBV infection. Recently, DCs treated 
with peptide inhibitors of IL-10 were shown to induce strong anti-HCV T cell response in 
HCV transgenic mice (Díaz-Valdés et al., 2011), suggesting a strategy to augment the 
immunogenic function of DCs. Moreover, when intrahepatic antigen-presenting cells, 
including DCs, were activated by injection of an anti-CD40 agonistic antibody, HBV 
replication was inhibited by a noncytopathic mechanism possibly through production of 
antiviral cytokines such as TNF- and IL-12 (Kimura et al., 2002a). Although no CTL 
response against HBV antigens was reported in this study, the in vivo activation of DCs 
could be an alternative way for inducing antiviral immune responses including possible 
activation of CTLs against HBV. In humans, injection of activated DCs loaded with HBV 
peptide or protein achieved a reduction in HBV DNA level in some patients (Chen et al., 
2005, Luo et al., 2010). HBeAg negativity was achieved in more than half of the treated 
patients in one study (Chen et al., 2005). Although preparation of activated and mature DCs 
incurs financial costs and requires experienced researchers, immunotherapy with DCs is a 
promising method. 
5.2.5 Natural Killer T (NKT) cells  
A single injection of -galactosylceramide abolished HBV replication by activating NKT 
cells in the liver in HBV transgenic mice (Kakimi et al., 2000). However, -
galactosylceramide was poorly tolerated in humans and showed no clear antiviral effect 
(Woltman et al., 2009), possibly due to smaller numbers of NKT cells in the human liver 
than in the mouse liver. 
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5.2.6 Cytokines and Thymosin-1 (Talpha1) 
Cytokines such as IL-12 (Cavanaugh et al., 1997) and IL-18 (Kimura et al., 2000b) were 
shown to inhibit HBV replication noncytopathically in HBV transgenic mice. In humans, 
GM-CSF (Martin et al., 1993, Wang et al., 2002) and IL-12 (Carreño et al., Zeuzem et al., 2001, 
Rigopoulou et al., 2005) have been used for treatment with some antiviral effects. They have 
been used as monotherapy or in combination with HB vaccine or lamivudine.  
Talpha1, a synthetic 28-amino acid peptide, is able to enhance the Thl immune response and 
also exerts a direct antiviral mechanism of action. It has been used for the treatment of 
chronic HBV (Arase et al, 2003, Iino et al., 2005, You et al., 2006, Lee et al., 2008) and HCV 
(Poo et al., 2008) infection in humans, and showed antiviral effect with some efficacy. 
Although antiviral effect by the addition of Talpha1 to lamivudine or IFN- therapy was 
controversial, a meta analysis demonstrated that the combination therapy with lamivudine 
and Talpha1 showed significantly higher rates of ALT normalization, virological response, 
and HBeAg seroconversion as compared with lamivudine monotherapy (Zhang et al., 2009). 
It is of note that HBeAg seroconversion rate was 45% in the combination group, which was 
significantly higher than that with lamivudine monotherapy (15%).    
 
DCs 
Akbar et al, 2010; DCs from peripheral blood and pulsed with HBsAg/HBcAg could 
induce HBsAg- and HBcAg-specific T cell proliferation in CHB patients. 
PD-1 
Nakamoto et al, 2009; CTLA-4 is preferentially expressed in PD-1+ T cells from the liver 
with chronic HCV infection, and coexpression of CTLA-4 and PD-1 is associated with T 
cell dysfunction. Combined blockade of these molecules, but not blocking of either 
molecule, can reverse CD8+ T cell exhaustion. 
Ha et al, 2008; Blocking PD-1, CTLA-4 and IL-10 combined with therapeutic vaccination 
could synergistically enhance functional CD8+ T cell response and improve viral control 
in chronically infected mice. Moreover, addition of stimulatory signals, such as IL-2, 
could further increase the efficacy of the therapy. 
CD244 
Raziorrouh et al, 2010; PD-1 and CD244 are highly coexpreesed on virus-specific CD8+ T 
cells in chronic HBV infection. Blocking signals through CD244 and its ligand CD48 could 
restore T cell dysfunction independent of the PD-1 pathway.  
Tim-3 
McMahan et al, 2010; Blockade of Tim-3 on human HCV-specific CTLs increased 
cytotoxicity against an HCVAg-expressing hepatocyte cell line that expresses HCV 
epitopes. 
Golden-Mason et al, 2009; Tim-3 expression was increased on both CD4+ and CD8+ T cells 
in chronic hepatitis C infection, and PD-1/Tim-3 double positive T cells are accumulated 
in the liver with chronic hepatitis C. Blocking Tim-3/Tim-3 ligand induced T cell 
proliferation and IFN- production in response to HCV antigens.    
Gene transfection 
Zhang et al, 2010; Human T cells transduced with HCV TCR specific for HCV NS3 1071-1081 
(HLA A2-restricted epitope) recognize the peptide and produced IFN-, IL-2 and TNF-.  
PD-1; programmed death-1, CTLA-4; cytotoxic T lymphocyte antigen-4, Tim-3; T-cell immunoglobulin 
and mucin domain-containing molecule-3  
Table 3. Human basic research for improvement of immunotherapy for viral hepatitis.  
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Moreover, there have been several basic attempts to improve the efficacy of immunotherapy 
(Table 3). Among these reports, augmentation or restoration of T cell response by blocking 
the inhibitory signals have been extensively analyzed in vitro. It has been demonstrated that 
exhausted T cells express not only PD-1, but also CTLA-4 (Nakamoto et al., 2009), CD244 
(Raziorrouch et al., 2010) or Tim-3 (Golden-Mason et al., 2009), and blocking of these 
molecules in combination could be better than blocking any single molecule to achieve full 
activation of the exhausted T cells. 
6. Conclusion 
There have been several attempts to apply immunotherapy for the control of chronic HBV 
and HCV infection, and some of the data are promising. Viral suppression, stimulation of 
antiviral immune response with cytokines, DNA or DC immunization and suppression of 
the immunoinhibitory signals must be combined to achieve desirable antiviral effects. 
Further studies are required to explore the best protocols and their most efficient 
combinations to become a promising and practical treatment. 
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